Quality of Anticoagulation With XXXX Antagonists.

@entity1 @entity64 @entity101 @entity548 @entity2067 @entity409 @entity955 @entity299 @entity3619 @entity285
BACKGROUND: @entity2067 antagonists (VKA) have a narrow therapeutic range, and literature analysis reveals poor quality of anticoagulation control. We sought to assess the prevalence of poor anticoagulant control in @entity1 under VKA treatment in the prevention of @entity64 for @entity955 ( @entity955 ). HYPOTHESIS: Control of anticoagulation with VKA is inadequate in a high percentage of @entity1 with @entity955 . METHODS: @entity1 with @entity955 under VKA treatment were prospectively recruited in this observational registry. The sample comprised 948 @entity1 . The estimated time spent in the therapeutic range (TTR) was calculated, and variables related with a TTR >65% were analyzed. RESULTS: Mean age was 73.8    9.4 years, and 42.5% of the @entity1 were @entity1 . Mean TTR was 63.77%    23.80% for the direct method and 60.27%    24.48% for the Rosendaal method. Prevalence of poor anticoagulation control was 54%. Variables associated with good anticoagulation control were university studies (odds ratio [OR]: 1.99, 95% confidence interval [CI]: 1.08-3.64), @entity3619 (OR: 8.15, 95% CI: 1.57-42.24), low comorbidity expressed as Charlson index (OR: 0.87, 95% CI: 0.76-0.99), no previous @entity299 (OR: 0.64, 95% CI: 0.41-0.98), lower risk of @entity548 assessed as @entity101 , @entity409 , @entity64 , @entity548 history or predisposition, labile international normalized ratio, elderly age, and use of drugs or @entity285 (HAS-BLED; OR: 0.81, 95% CI: 0.69-0.95), and lower heart rate (OR: 0.99, 95% CI: 0.98-0.99). CONCLUSIONS: @entity1 who receive VKA to prevent @entity64 for @entity955 spend less than half the time within therapeutic range.
